{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:33:23Z","timestamp":1769603603647,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cllc.2022.07.014","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T09:59:52Z","timestamp":1659866392000},"page":"e536-e539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-1350","authenticated-orcid":false,"given":"Kyung Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Kyung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang Ho","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong In","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.07.014_bib0001","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.014_bib0002","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.014_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.014_bib0004","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.014_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.014_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.014_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.014_bib0008","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.014_bib0009","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.014_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/jca.26494","article-title":"First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease","volume":"10","author":"Xu","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.cllc.2022.07.014_bib0011","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2022.07.014_bib0012","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicenter, phase 1-2 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.014_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2022.07.014_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.02.020","article-title":"Patterns of progression on osimertinib in EGFR T790M positive NSCLC: a Swiss cohort study","volume":"130","author":"Schmid","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.07.014_bib0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:31Z","timestamp":1761506071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1525730422001693"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}